New pill AND019 takes on tough breast cancer in first human test
NCT ID NCT05187832
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new oral drug called AND019 in 61 postmenopausal women with advanced or metastatic ER+/HER2- breast cancer who have not responded to standard treatments. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage. It is a first-in-human study, so results are very preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AND019 (oral capsule)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced ER+/HER2- breast cancer who have run out of standard therapies.
What could go wrong
This is a very early (Phase 1) and small (61 people) trial focused on safety, so it is far from proving effectiveness. The drug may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States